Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Want To Run Better? Try Focusing Your Eyes Straight Ahead
SATURDAY, June 28, 2025 — If you’re looking to boost your running performance, try this simple tip: Keep your eyes on the finish line.New research shows that n...
27.2 Million People of All Ages Uninsured in 2024 in the United States
FRIDAY, June 27, 2025 -- A total of 27.2 million people of all ages were uninsured in 2024, marking a nonsignificant increase from 25.0 million in 2023...
32 Percent of U.S. Adults Consumed Fast Food on a Given Day in 2021 to 2023
FRIDAY, June 27, 2025 -- Over 30 percent of adults and children consumed fast food on a given day during August 2021 to August 2023, according to two reports...
Disparities Seen in Continuous Glucose Monitor Rx by Language Preference
FRIDAY, June 27, 2025 -- For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language...
Survey Shows Few Adults Recognize Testicular Cancer as Affecting Young Men
FRIDAY, June 27, 2025 -- Only one in 10 U.S. adults correctly identified testicular cancer as most commonly affecting men under age 40, according to a survey...
U.S. Stops Funding for Gavi Global Vaccine Program, Sparking Backlash
FRIDAY, June 27, 2025 — The United States will stop sending money to Gavi, a global group that helps vaccinate children in low-income countries, U.S...
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
FRIDAY, June 27, 2025 -- For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant...
From Transgender Care To Vaping: Key Takeaways From SCOTUS 2025 Term
FRIDAY, June 27, 2025 — From allowing states to ban gender-transition care and sales of flavored vapes to minors to rolling back the landmark Clean Air...
RFK Jr.-Appointed Vaccine Panel Removes Flu Shot Ingredient
FRIDAY, June 27, 2025 — A U.S. vaccine advisory panel voted Thursday to stop recommending flu shots that contain thimerosal, a move that experts say may...
COVID Vaccine Labels To Warn of Rare Heart Risk
FRIDAY, June 27, 2025 — The U.S. Food and Drug Administration (FDA) has added new warnings to the Pfizer and Moderna COVID-19 vaccines about a rare heart...
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical...
FDA Approves Benlysta (belimumab) Autoinjector for Children with Active Lupus Nephritis
Philadelphia, PA June 24 2025 -- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector...
Datroway Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Tokyo and Basking Ridge, NJ – June 23, 2025 – Datroway (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult...
Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
TARRYTOWN, N.Y. and PARIS, June 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and...
FDA Approves Harliku (nitisinone) for the Treatment of Patients with Alkaptonuria
BOSTON, Massachusetts and Cambridge, UK – June 19, 2025 – Cycle Pharmaceuticals announced that the FDA has approved Harliku (nitisinone) Tablets...
FDA Approves Yeztugo (lenacapavir) as the First and Only HIV Prevention Option Offering 6 Months of Protection
FOSTER CITY, Calif.--(BUSINESS WIRE) June 18, 2025 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has...
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 17, 2025-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and...
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Jun. 13, 2025-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food...
Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for Brimochol PF for the Treatment of Presbyopia
LONDON, United Kingdom and SEATTLE, Wash., June 03, 2025 – Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology...
Linerixibat New Drug Application (NDA) Accepted for Review by the US FDA for Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC)
June 2, 2025 -- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the NDA for linerixibat, an...
Riliprubart Earns Orphan Drug Designation in the US for Antibody-Mediated Rejection in Solid Organ Transplantation
Paris, June 25, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of...
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-Positive NSCLC
CAMBRIDGE, Mass., June 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely...
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late...
Results From Amgen's Phase 2 Obesity Study of Monthly MariTide Presented at the American Diabetes Association 85th Scientific Sessions
THOUSAND OAKS, Calif., June 23, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart...
Novo Nordisk's Mim8 Prophylaxis Treatment Shown to be Well-Tolerated When Switching from Emicizumab in People with Hemophilia A in New Phase 3 Data
Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.